恩替卡韦治疗合并肺结核的慢性HBV携带者效果观察

洪友志; 黄记水; 洪文聪; 江涛源

doi:10.3969/j.issn.1001-5256.2016.11.015

恩替卡韦治疗合并肺结核的慢性HBV携带者效果观察

DOI: 10.3969/j.issn.1001-5256.2016.11.015

南安市医院感染科

基金项目:

泉州市科技局2012年度第二批指导性科技计划项目(7-340泉科【2012】189号)；

详细信息

中图分类号: R521;R512.62
计量
- 文章访问数: 2319
- HTML全文浏览量: 2
- PDF下载量: 514
- 被引次数: 0
出版历程
- 出版日期: 2016-11-20

Clinical effect of entecavir combined with antituberculosis therapy in patients with tuberculosis complicated by chronic HBV infection

Research funding:

摘要

摘要:
目的探讨肺结核合并慢性HBV携带患者抗结核治疗的同时应用恩替卡韦治疗的临床效果。方法收集2013年1月-2015年12月南安市医院收治的108例肺结核合并慢性HBV携带者,分为恩替卡韦组（n=58）和对照组（n=50）。恩替卡韦组在给予抗结核药物治疗前1个月至抗结核治疗全程均采用恩替卡韦进行干预,对照组单纯使用抗结核药物治疗,比较2组肝损伤及临床症状的发生率、肝功能异常出现时间及肝功能恢复的时间。计量资料组间比较采用独立样本t检验,计数资料组间比较采用χ2检验。结果恩替卡韦组与对照组肝功能异常发生率（29.31%vs 64.00%）、肝损伤临床症状发生率（17.24%vs 28.00%）比较,差异均有统计学意义（χ2值分别为8.475、5.534,P值均<0.05）;恩替卡韦组与对照组肝功能异常出现及恢复正常的时间分别为（25.1±10.2）d vs（20.1±8.9）d、（26.5±9.8）d vs（32.6±11.2）d,2组比较差异均有统计学意义（t值分别为2.675、3.778,P值均<0.05）。结论恩替卡韦能明显降低肺结核合并慢性HBV携带者抗结核治疗所引起的肝...
- 肝炎病毒,乙型 /
- 结核,肺 /
- 肝炎,中毒性 /
- 恩替卡韦
Abstract:
Objective To investigate the clinical effect of entecavir combined with antituberculosis therapy in patients with tuberculosis complicated by chronic HBV infection. Methods A total of 108 patients with tuberculosis complicated by chronic HBV infection were divided into entecavir group with 58 patients and control group with 50 patients. The patients in the entecavir group were given entecavir from1 month before antituberculosis therapy to the end of antituberculosis therapy,and those in the control group were given antitubercular agent alone. The incidence of liver injury and clinical symptoms,time to appearance of abnormal liver function,and time to liver function recovery were compared between the two groups. The two- independent- samples t test was used for comparison of continuous data between groups,and the chi- square test was used for comparison of categorical data between groups. Results Compared with the control group,the entecavir group had significantly higher incidence rates of abnormal liver function( 29. 31% vs 64. 00%,χ2= 8. 475,P < 0. 05) and clinical symptoms of liver injury( 17. 24% vs 28. 00%,χ2= 5. 534,P < 0. 05). There were significant differences in the time to appearance of abnormal liver function( 25. 1 ± 10. 2 d vs 20. 1 ± 8. 9 d,t = 2. 675,P < 0. 05) and time to liver function recovery( 26. 5 ± 9. 8 d vs 32. 6 ±11. 2 d,t = 3. 778,P < 0. 05). Conclusion Entecavir can significantly reduce the incidence of liver injury caused by antituberculosis therapy,postpone the time to appearance of liver injury,and accelerate liver function recovery in patients with tuberculosis complicated by chronic HBV infection.
- hepatitis B virus /
- tuberculosis,pulmonary /
- hepatitis,toxic /
- entecavir

HTML全文

参考文献(19)

[1] Chinese Society of Hepatology,Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B(2010 version)[J].J Clin Hepatol,2011,27(1):1-16.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版)[J].临床肝胆病杂志,2011,27(1):1-16.

[2]XIONG Z,BAI LQ,WANG XJ,et al.Study on the incidence and risk factors of adverse reactions of anti-tuberculosis drugs in 115 new smear positive pulmonary tuberculosis patients[J].Pract Prevent Med,2015,22(5):537-540.(in Chinese)熊姿,白丽琼,王孝君,等.115例初治涂阳肺结核患者抗结核药物不良反应发生率和影响因素研究[J].实用预防医学,2015,22(5):537-540.

[3]PAN L,JIA ZS,CHEN L,et al.Effect of anti-tuberculosis therapy on liver function of pulmonary tuberculosis patients infected with hepatitis B virus[J].World J Gastroenterol,2005,11(16):2518-2521.

[4]LAI RT,CHEN CW.Antituberculosis drug-induced liver damage[J].Chin J Hepatol,2011,19(8):634-636.(in Chinese)赖荣陶,陈成伟.抗结核药物所致肝损伤[J].中华肝脏病杂志,2011,19(8):634-636.

[5]MA CC,ZHAI XH,QIN LY,et al.Study on the incidence and risk factors of liver injury in Uighur tuberculosis patients[J].Chin J Dis Control Prevent,2016,20(1):17-20.(in Chinese)马晨晨,翟啸虎,秦丽岩,等.维吾尔族肺结核患者肝损害的发生率及相关因素的调查[J].中华疾病控制杂志,2016,20(1):17-20.

[6]ZHANG PY.Guidelines for the diagnosis and treatment of tuberculosis[J].Chin J Tuberc Respir Dis,2001,24(2):70-74.(in Chinese)张培元.肺结核诊断和治疗指南[J].中华结核和呼吸杂志,2001,24(2):70-74.

[7]HU Q,LIU W,SHAO H.Research advances in pharmacotherapy for drug-induced liver injury[J].Chin J Clin Pharmacol Ther,2016,21(2):231-236.(in Chinese)胡琴,刘维,邵宏.药物性肝损伤的药物治疗研究进展[J].中国临床药理学与治疗学,2016,21(2):231-236.

[8]AGA S,BAI JR,PRAMANIK S,et al.Monitoring and management of antituberculosis drug induced hepatotoxicity[J].Gastroenterology and Hepatology,2005,20(11):1745-1752.

[9]FERNANDEZ VA,SOPEFIA B,FERNANDEZ VJ,et al.The influence of risk factors on the severity of antituberculosis drug-induced hepatotoxicity[J].Tuberc Lung Dis,2004,8(12):1499-1505.

[10]NANASHIMA K,MAWATARI T,TAHARA N,et al.Genetic variants in antioxidant pathway:risk factors for hepatotoxicity in tuberculosis patients[J].Tuberculosis(Edinb),2012,92(3):253-259.

[11]ZHANG HY,CHEN BF,ZHENG RD,et al.Hepatic histopathological changes and clinical analysis of asymptomatic HBV carriers[J].Mod Med Health,2011,27(20):3054-3056.(in Chinese)张惠勇,陈碧芬,郑瑞丹,等.乙型肝炎病毒携带者的肝组织病理与临床分析[J].现代医药卫生,2011,27(20):3054-3056.

[12]PENG YC,LIN CL,KAO CH.Increased risk of liver cirrhosis fortuberculosis infection:response to Shen[J].Eur J Clin Invest,2015,45(9):1001-1002.

[13]WU LX,LIN SM,ZHANG X,et al.Dynamic changes in B7-H1expression on peripheral blood mononuclear cel s in chronic hepatitis B patients treated with entecavir[J].J Clin Hepatol,2014,30(9):929-931.(in Chinese)吴列秀,蔺淑梅,张曦,等.接受恩替卡韦治疗的慢性乙型肝炎患者外周血单个核细胞BT-H1表达的动态变化[J].临床肝胆病杂志,2014,30(9):929-931.

[14]LUO J,DU ZH,ZHOU XQ.Evaluation of curative effect of plasma exchange combined with entecavir in treatment of chronic severe hepatitis B[J].Int J Virol,2015,22(2):120-124.(in Chinese)罗君,杜宗汉,周晓晴.血浆置换联合恩替卡韦治疗慢性重型乙型病毒性肝炎的疗效观察[J].国际病毒学杂志,2015,22(2):120-124.

[15]CHANG TT,GISH RG,de MAN R,et al.A comparison of entecavir and lamivudine for HBeA g-positive chronic hepatitis B[J].N Engl J Med,2006,354(10):1001-1010.

[16]LAI CL,SHOUVAL D,LOK AS,et al.Entecavir versus lamivudine for patients with HBeA g-negative chronic hepatitis B[J].N Engl J Med,2006,354(10):1011-1020.

[17]SHANG P,XIA Y,LIU F,et al.Incidence,clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury(ATLI)in China[J].PLoS One,2011,6(7):e21836.

[18]ZHENG YX,MA SJ,TAN DM,et al.A meta-analysis of liver lesions in hepatitis B patients undergoing anti-tuberculosis therapy[J].Chin J Hepatol,2014,22(8):585-589.

[19]KAPLOWITZ N.Drug-induced liver disorders:implications for drug development and regulation[J].Drug Safety,2001,24(8):483-490.

施引文献

资源附件(0)

访问统计